UPDATE: Will Biogen ever publish the trial results for its new Alzheimer’s drug?
Usually when a new drug is approved by the FDA, physicians who might use that drug can turn to the medical literature for a deeper understanding of who exactly might benefit from it, what exactly occurred in the clinical trials (beyond the company’s press release), and why the agency signed off on it.
But in the case of Biogen’s new controversial Alzheimer’s drug Aduhelm (aducanumab), it’s unclear if the company will go the extra mile and try to publish the data, particularly as the only positive data was from a post-hoc analysis of one of the two trials that failed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.